Macular degeneration treatment market Estimated global elderly population of 1 billion 2020 2050
DUBLIN, March 26, 2024 (Globe Newswire) — The “Macular Degeneration Treatment – Market Share Analysis, Industry Trends and Statistics, Growth Forecasts 2021-2029” report has been added. ResearchAndMarkets.com Recruitment.
Growth trajectory of macular degeneration treatment market
The latest industry report indicates that the global macular degeneration treatment market is poised for significant growth, with the market expected to advance at a compound annual growth rate (CAGR) of 8.51% from 2024 to 2029. It is projected to grow to US$23.29 billion by 2019. This growth can be attributed to the increasing prevalence of retinal diseases, the aging of the world's population, and increased research and development efforts in this field.
Impact of the new coronavirus infection and subsequent market recovery
The COVID-19 pandemic has impacted a variety of sectors, including macular degeneration treatment services. The marked decline in clinic visits and treatments received highlighted the significant disruption to eye care due to the pandemic. However, with the advent of vaccination programs and the lifting of restrictions, the market is rebounding and adopting new strategies for continuous care delivery.
Factors and constraints in the field of macular degeneration treatment
The increasing incidence of retinal diseases is driving the expansion of the macular degeneration treatment market. With a growing elderly population at risk for age-related macular degeneration and other retinal diseases, the demand for treatment options is rapidly increasing. At the same time, intense research and development, exemplified by recent clinical trials, is driving advances in treatment methods and offering promise for improved patient outcomes. Conversely, the trajectory of the macular degeneration treatment market is being challenged by factors such as the prevalence of off-label drug use and lack of widespread awareness about the disease, which are likely to hinder market growth. there is.
Segment insights and regional advantages
The wet form of age-related macular degeneration, characterized by abnormal growth of blood vessels under the retina, dominates the market share. This is primarily due to the growing elderly population, who are most at risk for the disease, as well as groundbreaking research and treatment innovations. North America in particular leads the market due to its robust infrastructure, major market players, and active government initiatives that support continuous research and product development.
Future outlook and market participants
Looking to the future, a dynamic industry is poised to meet the challenges of macular degeneration through innovation and strategic market efforts, with sustained growth expected within the North American region and even globally. I understand this. Prominent players operating within the market play a vital role in shaping the competitive landscape through their strategic initiatives, product launches, and consistent focus on research and development. As the industry navigates the impact of an aging population and technological advances, the macular degeneration treatment market is proving a constant pursuit of health and well-being in the face of chronic, life-altering conditions. I am.For media inquiries, please contact us here [insert contact information].
Some of the companies mentioned in this report include:
-
F. Hoffman La Roche Co., Ltd.
-
Novartis AG
-
Pfizer Japan Inc
-
panoptica
-
Bausch Health Companies Inc.
-
Regeneron Pharmaceuticals Co., Ltd.
-
Airy Pharmaceutical Co., Ltd.
-
Regenxbio Co., Ltd.
-
Bayer AG
-
Lineage Cell Therapeutics
-
Ocugen Co., Ltd.
-
clover therapeutics
-
ONL Therapeutics
-
Meira GTx
-
Oxurion
Covers key topics
1.First of all
1.1 Research prerequisites
1.2 Scope of investigation
2 Research method
3 Executive summary
4 Market dynamics
4.1 Market overview
4.2 Market drivers
4.2.1 Increasing burden of retinal diseases
4.2.2 Rapid increase in elderly population
4.2.3 Increase in R&D investment
4.3 Market constraints
4.3.1 Increased use of off-label drugs
4.3.2 Lack of awareness about AMD
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining power of buyers/consumers
4.4.2 Bargaining power of suppliers
4.4.3 Threat of new entrants
4.4.4 Threat of substitute products
4.4.5 Intensity of competition
5 Market Segmentation (Market Value by Size – USD Million)
5.1 By type
5.1.1 Dry age-related macular degeneration
5.1.2 Wet age-related macular degeneration
5.2 Disease stages
5.2.1 Early AMD
5.2.2 Medium AMD
5.2.3 Late AMD
5.3 By treatment type
5.3.1 Drugs
5.3.1.1 Anti-vascular endothelial growth factor
5.3.1.2 Dietary supplements
5.3.1.3 Other drugs
5.3.2 Device
5.3.2.1 Glasses
5.3.2.2 Contact lenses
5.3.2.3 Other devices
5.3.3 Surgery
5.3.3.1 Laser surgery
5.3.3.2 Other surgeries
5.4 By route of administration
5.4.1 Venous route
5.4.2 Intravitreal route
5.5 By sales channel
5.5.1 Outpatient surgery center
5.5.2 Hospital
5.5.3 Other sales channels
5.6 Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia Pacific Region
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of the Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive environment
6.1 Company profile
6.1.1 F Hoffman La Roche Ltd.
6.1.2 Novartis AG
6.1.3 Pfizer Inc.
6.1.4 Panoptica
6.1.5 Bausch Health Companies, Inc.
6.1.6 Regeneron Pharmaceuticals Co., Ltd.
6.1.7 Aerie Pharmaceutical Inc.
6.1.8 REGENXBIO Co., Ltd.
6.1.9 Bayer AG
6.1.10 Lineage Cell Therapy
6.1.11 Ocugen Inc.
6.1.12 Clover Therapeutics
6.1.13 ONL therapeutics
6.1.14 Meira GTx
6.1.15 Oxurion
7 Market opportunities and future trends
For more information about this report, please visit https://www.researchandmarkets.com/r/x3px8h.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
